Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.20    -0.40 (-0.32%)
Bid:
125.20
Ask:
125.80
Spread: 0.60 (0.479%)
Market Cap: £307.19m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director Declaration

10 Nov 2022 17:00

RNS Number : 0398G
PureTech Health PLC
10 November 2022
 

10 November 2022

 PureTech Health plc

 

Director Declaration

 

Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company's Board, has been appointed as President and Chief Executive Officer and a member of the Board of Biogen Inc. (Nasdaq: BIIB) with effect from November 14, 2022. 

 

For further information please contact:

Bharatt Chowrira, PhD, JD, President and Chief Business, Finance and Operating Officer, member of the Board of Directors and Company Secretary: +1 617 482 2333

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNEAKFEFFPAFFA
Date   Source Headline
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:02 pmRNSPrice Monitoring Extension
5th Mar 20204:40 pmRNSSecond Price Monitoring Extn
5th Mar 20204:35 pmRNSPrice Monitoring Extension
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Mar 20207:00 amRNSClinical Trial Initiated Of Wholly-Owned Candidate
2nd Mar 20207:00 amRNSTotal Voting Rights
27th Feb 20204:41 pmRNSSecond Price Monitoring Extn
27th Feb 20204:36 pmRNSPrice Monitoring Extension
25th Feb 20207:00 amRNSAkili ADHD Study in The Lancet Digital Health
18th Feb 20207:00 amRNSPRTC to Present at Leerink Healthcare Conference
3rd Feb 20204:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20204:35 pmRNSPrice Monitoring Extension
3rd Feb 20207:00 amRNSTotal Voting Rights
23rd Jan 20207:00 amRNSPureTech Receives $200M from KRTX Shares
15th Jan 20201:04 pmRNSAkili's New ADHD Trial Met Primary Endpoint
13th Jan 202012:07 pmRNSSecond Price Monitoring Extn
13th Jan 202012:02 pmRNSPrice Monitoring Extension
2nd Jan 20207:00 amRNSTotal Voting Rights
19th Dec 20197:00 amRNSFollica Positive Androgenetic Alopecia Study
17th Dec 201912:00 pmRNSGelesis Partners with US Telehealth Provider
12th Dec 20191:04 pmRNSAkili Meets Primary Endpoint in MDD Clinical Trial
10th Dec 201912:02 pmRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSVedanta & BMS Begin Immuno-Oncology Clinical Study
9th Dec 20197:00 amRNSGelesis Attracts $84M in New Capital for Launch
5th Dec 20197:00 amRNSVedanta MultiDrug Resistance Program Granted $5.8M
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 201912:02 pmRNSPrice Monitoring Extension
21st Nov 20197:00 amRNSKaruna Prices $250M Follow-On Offering
18th Nov 201911:03 amRNSKaruna Successful Ph2 Schizophrenia Study Readout
15th Nov 201912:51 pmRNSresTORbio Update on Phase 3 Trial
13th Nov 20197:00 amRNSPureTech to Present at Jefferies London Conference
5th Nov 20191:00 pmRNSPRTC Presents Novel Oncology Program Data at SITC
5th Nov 201911:00 amRNSGelesis Shares New Plenity Safety & Efficacy Data
28th Oct 201912:07 pmRNSSecond Price Monitoring Extn
28th Oct 201912:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.